Brickell Biotech (BBI) Stock Price
Brickell Biotech Price
Revenue at Brickell Biotech has contracted by 0.8% per year over the past 19 years to 6.94 M USD. Brickell Biotech's net margin stands at -303.9%, up from -1,002.1% several years earlier. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.
Brickell Biotech stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Brickell Biotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Brickell Biotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Brickell Biotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Brickell Biotech Price |
|---|
Brickell Biotech Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Brickell Biotech Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30.00 | 17.00 | 7.00 | 15.00 | 20.00 | 14.00 | 13.00 | 1.00 | 7.00 | 1.00 | – | 6.00 | 7.00 | 6.00 | 8.00 | 11.00 |
| 275.00 | -43.33 | -58.82 | 114.29 | 33.33 | -30.00 | -7.14 | -92.31 | 600.00 | -85.71 | – | – | 16.67 | -14.29 | 33.33 | 37.50 |
| 63.33 | 100.00 | -57.14 | 26.67 | 50.00 | 57.14 | 53.85 | 100.00 | 100.00 | 100.00 | – | 16.67 | 100.00 | 100.00 | 100.00 | 100.00 |
| 19.00 | 17.00 | -4.00 | 4.00 | 10.00 | 8.00 | 7.00 | 1.00 | 7.00 | 1.00 | 1.00 | 1.00 | 7.00 | 6.00 | 8.00 | 11.00 |
| -7.00 | -23.00 | -31.00 | -16.00 | -9.00 | -9.00 | -13.00 | -19.00 | -24.00 | -20.00 | -39.00 | -21.00 | -27.00 | -26.00 | -25.00 | -24.00 |
| -23.33 | -135.29 | -442.86 | -106.67 | -45.00 | -64.29 | -100.00 | -1,900.00 | -342.86 | -2,000.00 | – | -350.00 | -385.71 | -433.33 | -312.50 | -218.18 |
| -7.00 | -22.00 | -31.00 | -16.00 | -9.00 | -8.00 | -12.00 | -16.00 | -23.00 | -20.00 | -39.00 | -21.00 | – | – | – | – |
| -76.67 | 214.29 | 40.91 | -48.39 | -43.75 | -11.11 | 50.00 | 33.33 | 43.75 | -13.04 | 95.00 | -46.15 | – | – | – | – |
| 2.81 | 2.81 | 2.81 | 2.81 | 2.81 | 2.81 | 2.81 | 2.81 | 2.81 | 2.81 | 2.81 | 2.81 | 2.81 | 2.81 | 2.81 | 2.81 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Brickell Biotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Brickell Biotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Brickell Biotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Brickell Biotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Brickell Biotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Brickell Biotech stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Brickell Biotech Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Brickell Biotech business model & stock analysis
Brickell Biotech SWOT Analysis
Strengths
1. Strong research and development capabilities, enabling the company to develop innovative biotech products.
2. Established reputation and expertise in the biotech industry.
3. Strong financial position and a solid balance sheet, providing stability and potential for growth.
4. Robust intellectual property portfolio, protecting the company's innovations and providing a competitive edge.
Weaknesses
1. Reliance on a limited product portfolio, which may expose the company to market fluctuations and competition.
2. Limited global presence and market reach, limiting potential growth opportunities.
3. High research and development costs, which may impact profitability in the short term.
Opportunities
1. Growing demand for biotech products and therapies, presenting opportunities for market expansion.
2. Increasing adoption of personalized medicine, offering potential for customized biotech solutions.
3. Potential partnerships and collaborations with established pharmaceutical companies, enabling access to larger markets and resources.
Threats
1. Intense competition within the biotech industry, posing a challenge to market share and pricing strategies.
2. Stringent regulatory requirements and lengthy approval processes, potentially delaying product launches.
3. Rapid technological advancements, leading to the emergence of substitute products or more efficient alternatives.
Brickell Biotech Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Brickell Biotech Segments
Brickell Biotech Revenue by Segment
3 Years
5 Years
Max
Details
Brickell Biotech Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Brickell Biotech historical P/E ratio, EBIT multiple, and P/S ratio
Brickell Biotech annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Brickell Biotech shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Brickell Biotech stock splits
Current Brickell Biotech forecasts and price targets in August 2026
Analyst Price Targets 2026Brickell Biotech Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/16/2022 | Maintained | Buy | – | |
| 5/13/2022 | Downgrade | BuyHold | – | |
| 3/8/2022 | Maintained | Outperform | – | |
| 1/18/2022 | Maintained | Buy | – | |
| 8/28/2020 | Maintained | Buy | – | |
| 8/25/2020 | Maintained | Outperform | 65 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Brickell Biotech Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/9/2023 | -1.55USD | - | 507,499.00USD | - | 2023 Q2 |
| 5/10/2023 | -1.50USD | - | 319,724.00USD | - | 2023 Q1 |
| 3/13/2023 | -1.11USD | - | 1.56 MUSD | - | 2022 Q4 |
| 11/7/2022 | -1.87USD | - | 209,770.00USD | - | 2022 Q3 |
| 8/11/2022 | -1.45USD | - | 3.18 MUSD | - | 2022 Q2 |
| 5/12/2022 | -2.61USD | - | 145,906.00USD | - | 2022 Q1 |
| 3/15/2022 | -3.86USD | - | 157,071.00USD | - | 2021 Q4 |
| 11/9/2021 | -5.68USD | - | 152,249.00USD | - | 2021 Q3 |
| 8/12/2021 | -5.68USD | - | 50,749.00USD | - | 2021 Q2 |
| 5/13/2021 | -5.23USD | - | 50,749.00USD | - | 2021 Q1 |
Brickell Biotech shareholder structure
| % | Name |
|---|---|
3.18899% | |
2.60611% | |
1.59536% | |
1.18876% | |
0.82067% | |
0.64084% |
Brickell Biotech Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
13.00% | SEC ↗ | |
13.00% | SEC ↗ | |
13.00% | SEC ↗ | |
13.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
9.99% | SEC ↗ | |
8.79% | SEC ↗ | |
8.79% | SEC ↗ |
Brickell Biotech Supply Chain
Brickell Biotech Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.27 | 0.78 | 0.72 | ||
| 2 | 0.25 | 0.98 | 0.72 | ||
| 3 | 0.14 | 0.88 | 0.31 |
Frequently asked questions about Brickell Biotech
Brickell Biotech Inc's business model focuses on the development and commercialization of innovative therapeutics for various skin conditions. With a strong emphasis on dermatology, the company aims to address unmet medical needs through cutting-edge research and development. By harnessing its proprietary delivery technologies and expertise in drug development, Brickell Biotech Inc strives to bring novel treatment options to patients suffering from conditions like hyperhidrosis and other dermatologic disorders. The company's commitment to advancing scientific knowledge and delivering effective therapies underscores its mission to improve patients' lives and enhance skin health.
Brickell Biotech Inc is primarily active in the healthcare and pharmaceutical industries. As a leading company in the field, Brickell Biotech focuses on the development and commercialization of innovative therapeutics for the treatment of various skin diseases, such as hyperhidrosis and acne. With its cutting-edge research and advanced formulations, Brickell Biotech aims to provide effective solutions that improve the lives of patients worldwide. By revolutionizing the dermatological market, Brickell Biotech Inc continues to establish itself as a key player in the healthcare industry, delivering innovative products backed by scientific expertise and a commitment to patient care.
The main competitors of Brickell Biotech Inc in the market are other pharmaceutical companies that focus on the development and commercialization of novel therapeutics. These may include companies such as Johnson & Johnson, Pfizer, Merck & Co., Inc., Bristol Myers Squibb, and Novartis.
Brickell Biotech Inc is a pharmaceutical company specializing in the development and commercialization of innovative therapies. Founded in 2009, Brickell Biotech has established a strong presence in the dermatology and infectious disease markets. With a mission to improve patients' lives, the company focuses on developing novel treatments addressing unmet medical needs. Brickell Biotech has a rich history of successful research and development, collaborating with leading clinicians and scientists. Its dedication to innovation and commitment to quality has positioned the company as a trusted healthcare partner. Brickell Biotech's continuous efforts in advancing medical solutions highlight its dedication to improving global health.
Brickell Biotech Inc has achieved significant milestones in its journey. These include the FDA approval of its novel therapeutic, sofpironium bromide gel, for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweating. This milestone demonstrates the company's commitment to addressing unmet medical needs. Furthermore, Brickell Biotech Inc has successfully completed Phase 3 clinical trials, showcasing the efficacy and safety of its product. The company's achievements reflect its dedication to developing innovative solutions to improve patients' quality of life. Brickell Biotech Inc's FDA approval and completion of pivotal trials signify substantial progress towards becoming a leading pharmaceutical player in the dermatology market.
Brickell Biotech Inc is primarily present in the United States.
Brickell Biotech Inc represents values of innovation, integrity, and dedication to improving patient lives. With a strong corporate philosophy focused on developing transformative therapeutics, Brickell Biotech is dedicated to advancing dermatology solutions for unmet medical needs. The company's commitment to excellence is reflected in its research and development efforts to bring novel treatments to market. Brickell Biotech's approach emphasizes collaboration, leveraging scientific expertise, and fostering strong relationships with healthcare professionals. By prioritizing patient well-being and employing cutting-edge technologies, Brickell Biotech Inc strives to make a positive impact on the lives of individuals with dermatological conditions.
8 analysts currently rate the Brickell Biotech stock: 6 recommend buying, 2 holding and 0 selling.
The Brickell Biotech share (BBI) is listed on 1 stock exchanges, including: NASDAQ (BBI).
Brickell Biotech Inc is an American biopharmaceutical company specializing in the development of products for the treatment of skin disorders. The company was founded in 2009 and is headquartered in Boulder, Colorado.
The revenue cannot currently be calculated for Brickell Biotech.
The profit cannot currently be calculated for Brickell Biotech.
The P/E ratio cannot be calculated for Brickell Biotech at the moment.
The P/S cannot be calculated for Brickell Biotech currently.
The Eulerpool Quality Score for Brickell Biotech is 2/10.
The ISIN of Brickell Biotech is US10802T1051. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Brickell Biotech is A2PRDX. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Brickell Biotech is BBI. The ticker symbol is used to trade Brickell Biotech shares on the stock exchange.
Brickell Biotech is assigned to the 'Health' sector.
The dividends of Brickell Biotech are distributed in USD.
Brickell Biotech stock
Brickell Biotech Peer Group
Brickell Biotech Ticker
Brickell Biotech FIGI
All fundamentals and in-depth analysis of Brickell Biotech
Our stock analysis for Brickell Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Brickell Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.